Aurinia Pharmaceuticals (AUPH) Liabilities and Shareholders Equity (2015 - 2026)
Aurinia Pharmaceuticals posted quarterly Liabilities and Shareholders Equity of $724.0 million for Q1 2026, up 43.41% year-on-year from $504.8 million in Q1 2025, and down 3.67% on a QoQ basis from $751.6 million in Q4 2025.
Aurinia Pharmaceuticals (AUPH) has 12 years of Liabilities and Shareholders Equity data on file, last reported at $724.0 million in Q1 2026.
- For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 43.41% year-over-year to $724.0 million; the trailing twelve-month figure through Mar 2026 stood at $2.5 billion (up 17.73% YoY), and the FY2025 full-year result was $751.6 million, up 36.49% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $724.0 million, down from $751.6 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $751.6 million in Q4 2025 and bottomed at $451.8 million in Q1 2023.
- The 5-year median for Liabilities and Shareholders Equity is $523.5 million (2024), against an average of $541.3 million.
- The widest annual swing landed in 2022, when Liabilities and Shareholders Equity dropped 13.34%; it then soared 43.41% in 2026.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $470.9 million in 2022, then grew by 16.4% to $548.1 million in 2023, then climbed by 0.47% to $550.6 million in 2024, then surged by 36.49% to $751.6 million in 2025, then decreased by 3.67% to $724.0 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $724.0 million (Q1 2026), $751.6 million (Q4 2025), and $527.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Aurinia Pharmaceuticals | 2.03 Bn | 1.65 Bn | 71.20 Mn | 724.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 724.00 Mn |
| Dec 31, 2025 | 751.59 Mn |
| Sep 30, 2025 | 527.53 Mn |
| Jun 30, 2025 | 502.56 Mn |
| Mar 31, 2025 | 504.85 Mn |
| Dec 31, 2024 | 550.65 Mn |
| Sep 30, 2024 | 549.36 Mn |
| Jun 30, 2024 | 523.53 Mn |
| Mar 31, 2024 | 516.63 Mn |
| Dec 31, 2023 | 548.06 Mn |
| Sep 30, 2023 | 555.01 Mn |
| Jun 30, 2023 | 548.90 Mn |
| Mar 31, 2023 | 451.76 Mn |
| Dec 31, 2022 | 470.86 Mn |
| Sep 30, 2022 | 488.29 Mn |
| Jun 30, 2022 | 482.15 Mn |
| Mar 31, 2022 | 506.90 Mn |
| Dec 31, 2021 | 543.37 Mn |
| Sep 30, 2021 | 360.07 Mn |
| Jun 30, 2021 | 386.27 Mn |
| Mar 31, 2021 | 417.08 Mn |
| Dec 31, 2020 | 463.66 Mn |
| Sep 30, 2020 | 461.75 Mn |
| Jun 30, 2020 | 278.02 Mn |
| Mar 31, 2020 | 297.90 Mn |
| Dec 31, 2019 | 324.30 Mn |
| Sep 30, 2019 | 150.84 Mn |
| Jun 30, 2019 | 151.24 Mn |
| Mar 31, 2019 | 164.50 Mn |
| Dec 31, 2018 | 145.86 Mn |
| Sep 30, 2018 | 157.70 Mn |
| Jun 30, 2018 | 167.86 Mn |
| Mar 31, 2018 | 176.41 Mn |
| Dec 31, 2017 | 189.85 Mn |
| Sep 30, 2017 | 199.83 Mn |
| Jun 30, 2017 | 207.80 Mn |
| Mar 31, 2017 | 219.69 Mn |
| Dec 31, 2016 | 57.00 Mn |
| Sep 30, 2016 | 33.25 Mn |
| Jun 30, 2016 | 30.19 Mn |
| Mar 31, 2016 | 27.75 Mn |
| Dec 31, 2015 | 33.57 Mn |
| Sep 30, 2015 | 38.94 Mn |
| Jun 30, 2015 | 44.38 Mn |
| Mar 31, 2015 | 48.01 Mn |